Titlebook: Management erfolgreicher Produkte; Arthur D. Little (Managing Director Europe) Textbook 1994 Springer Fachmedien Wiesbaden 1994 Design.Füh

CHARY

書目名稱Management erfolgreicher Produkte影響因子(影響力)




書目名稱Management erfolgreicher Produkte影響因子(影響力)學(xué)科排名




書目名稱Management erfolgreicher Produkte網(wǎng)絡(luò)公開度




書目名稱Management erfolgreicher Produkte網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Management erfolgreicher Produkte被引頻次




書目名稱Management erfolgreicher Produkte被引頻次學(xué)科排名




書目名稱Management erfolgreicher Produkte年度引用




書目名稱Management erfolgreicher Produkte年度引用學(xué)科排名




書目名稱Management erfolgreicher Produkte讀者反饋




書目名稱Management erfolgreicher Produkte讀者反饋學(xué)科排名

Ganglion-Cyst

Arthur D. Littleucidation of the action mechanisms helps to select proper antiarrhythmic drugs, improve antiarrhythmic effect, and reduce the incidence of adverse drug reaction. In this chapter, we discuss the mechanisms of antiarrhythmic and adverse proarrhythmic action of antiarrhythmic drugs according to the Sin

Aromatic

得罪人

Arthur D. Littleucidation of the action mechanisms helps to select proper antiarrhythmic drugs, improve antiarrhythmic effect, and reduce the incidence of adverse drug reaction. In this chapter, we discuss the mechanisms of antiarrhythmic and adverse proarrhythmic action of antiarrhythmic drugs according to the Sin

染色體

與野獸博斗者

Arthur D. Littlesible mechanisms of out-of-hospital cardiac arrest and sudden cardiac death (SCD). Defibrillation is the only predictably effective therapy for reverting VF and pulseless VT to an effective rhythm for restoration of blood flow. Current indications for implantation of implantable cardioverter-defibri

locus-ceruleus

發(fā)展

s underlying many disease processes. Mutations in cardiac ion channels have been identified as the basis of a wide range of inherited arrhythmia syndromes, including the long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome, short QT syndrome (SQTS),

思考

Synthesize